

8 March 2024

## Change of Director's Interest Notice

Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri" or the "Company"), provides the following Appendix 3Y "Change of Director's Interest Notice" for Nicholas Smedley. The Appendix 3Y reflects the issue of Shares and attaching options pursuant to placement as approved by shareholders at the Company's 15 November 2023 Annual General Meeting.

In relation to the late lodgement of the Appendix 3Y, the Company advises as follows:

1. The Appendix 3Y is being lodged late due to an administrative oversight.
2. The Company and the directors are aware of their obligations under ASX Listing Rules 3.19A and 3.19B and the late lodgement is due to an administrative oversight.
3. The Company believes that its current practices are adequate to ensure compliance with the ASX Listing Rules and appropriate for a company of its size.

-ENDS-

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.*

---

### About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management and Remote Patient Monitoring services. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia and in New York, USA.

For additional information about Respiri and its products, please visit [www.respiri.co](http://www.respiri.co)

### About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link <https://wheezo.com>

wheezo® is a registered trademark of Respiri Limited.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Respiri Limited
<b>ABN</b>	98 009 234 173

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Nicholas Smedley
<b>Date of last notice</b>	1 September 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	More Capital Holdings P/L (ATF More Capital Trust) More Investment Group P/L (ATF Bear Super Fund) Matriarch Rock P/L (ATF PJ Smedley Super Fund) – held in name of HSBC Custody Nominees (Australia) P/L
<b>Date of change</b>	21 November 2023
<b>No. of securities held prior to change</b>	4,612,395 ordinary shares (More Capital Holdings) 40,000,000 options (More Capital Holdings P/L) 5,301,818 ordinary shares (More Investment Group P/L) 5,545,455 ordinary shares (Matriarch Rock P/L)
<b>Class</b>	Ordinary shares and RSHO Listed Options
<b>Number acquired</b>	800,294 Ordinary shares and 400,147 RSHO Listed Options
<b>Number disposed</b>	Nil

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$0.034 per Share. The RSHO Listed Options were issued as free attaching Options on a one for two basis and were issued for nil cash consideration.
<b>No. of securities held after change</b>	5,412,689 ordinary shares (More Capital Holdings) 400,147 RSHO Listed Options (More Capital Holdings) 40,000,000 options (More Capital Holdings P/L) 5,301,818 ordinary shares (More Investment Group P/L) 5,545,455 ordinary shares (Matriarch Rock P/L)
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of shares and attaching options pursuant to Placement as approved by shareholders at the Company's 15 November 2023 AGM.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

**Part 3 – +Closed period**

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

---

<sup>+</sup> See chapter 19 for defined terms.